Early Stage Cost-Effectiveness Analysis of a Brca1-Like Test to Detect Triple Negative Breast Cancers Responsive to High Dose Alkylating Chemotherapy

Value in Health - United Kingdom
doi 10.1016/j.jval.2014.08.567
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

BRCA1/2-negative Hereditary Triple-Negative Breast Cancers Exhibit BRCAness

International Journal of Cancer
Cancer ResearchOncology
2017English

High XIST and Low 53BP1 Expression Predict Poor Outcome After High-Dose Alkylating Chemotherapy in Patients With a BRCA1-like Breast Cancer

Molecular Cancer Therapeutics
Cancer ResearchOncology
2015English

The Prognostic Value of BRCA1 Promoter Methylation in Early Stage Triple Negative Breast Cancer

journal of Cancer Therapeutics and Research
2014English

BRCA1-IRIS Inactivation Overcomes Paclitaxel Resistance in Triple Negative Breast Cancers

Breast Cancer Research
Cancer ResearchOncology
2015English

22p * Development of a Brca1-Like Signature in Triple Negative Breast Cancers Within the Rather (Rational Therapy for Breast Cancer) Consortium

Annals of Oncology
MedicineOncologyHematology
2014English

Genetic Variations in Triple-Negative Breast Cancers Undergoing Neo-Adjuvant Chemotherapy

2019English

Are Basal-Like and Non-Basal-Like Triple-Negative Breast Cancers Really Different?

Journal of Oncology
Oncology
2020English

Molecular Stratification of Triple-Negative Breast Cancers

Oncologist
Cancer ResearchMedicineOncology
2010English

High Prevalence of Preinvasive Lesions Adjacent to BRCA1/2-Associated Breast Cancers

Cancer Prevention Research
MedicineCancer ResearchOncology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy